Introduction {#s1}
============

Chronic Kidney Disease (CKD) is a long-term, progressive, and irreversible condition characterized by functional and structural kidney damages lasting for at least 3 months ([@B12]; [@B20]). Kidney transplantation is the optimal kidney replacement therapy for patients who have reached end-stage renal disease (ESRD) ([@B19]). Transplant recipients require life-long immunosuppression to prevent allograft rejection. Tacrolimus, a calcineurin inhibitor, is the most frequently used drug in kidney transplantation recipients. The impressive results of tacrolimus treatment, however, are offset by its side effects, narrow therapeutic index and variable and unpredictable pharmacokinetics ([@B17]). For this reason, therapeutic drug monitoring (TDM) is crucial in daily practice. Renal transplant recipients usually receive standard weight-based dose which is then adjusted according to TDM to maintain tacrolimus blood concentrations within the therapeutic range. However, using TDM do not guarantee optimal treatment efficacy or lack of rejections and adverse reactions ([@B3]; [@B22]). Genetic factors are considered to play important role in the interindividual and interethnic variability in pharmacokinetics of tacrolimus ([@B10]).

CYP3A5 is an enzyme responsible for the metabolism of tacrolimus. Single nucleotide polymorphisms in *CYP3A5* gene explain 40--50% of the variability in tacrolimus metabolism and clearance ([@B21]). The A to G transition at position 6986 in intron 3 of the *CYP3A5* gene is the most well-studied genomic variant which contributes to dose requirement of tacrolimus ([@B15]). *CYP3A5\*3* allele results in alternative spicing of the mRNA which leads to absence of CYP3A5 protein activity and is associated with reduced tacrolimus dose requirement ([@B9]). The presence of the wild-type allele (*CYP3A5\*1*) contributes significantly to the increase of CYP3A activity associated with recovery of renal function after transplantation ([@B16]). Two more variant alleles, *CYP3A5\*6* and *CYP3A5\*7*, result also at loss of expression of the functional protein in homozygotes ([@B3]).

Several studies in different populations have shown that *CYP3A5* expressors, who carry at least one *CYP3A5\*1* allele require 50% (1.5--2-fold) higher tacrolimus doses compared to *CYP3A5* non-expressors those who are homozygous for the variant alleles (*CYP3A5\*3*, *CYP3A5\*6*, or *CYP3A5\*7*) ([@B3]; [@B4]). However, this association between *CYP3A5* genotypes and tacrolimus dose requirement has not yet been studied in Egyptian kidney transplantation recipients.

In this study, we aimed to determine the allelic frequency of *CYP3A5\*3* among Egyptian patients that have undergone transplantation and to evaluate the influence of this polymorphism on tacrolimus daily dose and on metabolism rate in adult patients during the first year after kidney transplantation.

Materials and Methods {#s2}
=====================

Study Population {#s2_1}
----------------

For the present study, 76 unrelated kidney transplanted adult patients were enrolled in Urology and Nephrology Center at Mansoura University Hospital in Egypt. All patients underwent renal transplantation from living donors and were under tacrolimus immunosuppressive treatment for at least one year. Recipients received a standard bodyweight-based tacrolimus initial dose (day -1 before transplantation) of 0.1 mg/kg twice per day. Blood samples were collected into EDTA tubes and stored at -80°C till analyzed. Therapeutic drug monitoring was applied to all samples for dose adjustment. The target whole-blood concentration in early period after transplantation is 10--20 ng/ml and in the maintenance period (after 3 months) 5--10 ng/ml. Tacrolimus daily dose, tacrolimus blood levels, demographic, and clinical data were obtained from medical files of the patients at the beginning of the post-transplant period and at 12 months after transplantation. Patients with diarrhea or vomiting, liver disease, advanced renal dysfunction, or other disorders that could have altered the absorption of tacrolimus or patients that will be co-prescribed drugs that affect the pharmacokinetics of tacrolimus and its pharmacological effect (antifungals, antiepileptics, macrolide antibiotics) were excluded from the study.

The study was conducted in compliance with the declaration of Helsinki and was approved by the Ethics Committee of the Mansoura University Hospital and written informed consent was obtained from all subjects.

DNA Extraction and Genotyping {#s2_2}
-----------------------------

Total genomic DNA was extracted from the peripheral blood, followed by determination of its concentration and purity. The *CYP3A5* single nucleotide polymorphism (SNP) -- *CYP3A5\*3* (rs776746) was genotyped by PCR-restriction fragment length polymorphism (RFLP), using the SspI restriction endonuclease as previously described ([@B13]).

Statistical Analysis {#s2_3}
--------------------

Estimation of allele and genotype frequencies was performed using gene counting method and their deviation from Hardy-Weinberg equilibrium was assessed by Pearson's goodness of fit chi-square test (degree of freedom = 1). Continuous variables are shown as mean and standard deviation and qualitative data are expressed as frequency and percentage.

Continuous data were tested for normality using Kolmogorov-Smirnov and Shapiro-Wilk tests (p = 0.05) and visualized with Q-Q plots. Depending on the distribution, comparisons for variables between two groups were performed with two-tailed test or Wilcoxon test for related samples and with unpaired t-test or Mann-Whitney test for independent samples. The categorical data were analyzed using two-tailed Fisher's exact test.

In the present study patients were divided into two groups according to their genotype \[CYP3A5 expressors (\*1/\*1 or \*1/\*3) and CYP3A5 non-expressors (\*3/\*3)\]. Both groups were examined for statistically significant difference in dose requirements, tacrolimus blood levels, and C/D ratio (dose corrected trough concentration of Tac). These data were compared at different time points among related samples (patients with the same genotype) and at the same time points among independent samples (patients with different genotype).

Statistical analysis was performed using SPSS Statistics 25.0 (IBM SPSS software) and GraphPad Prism 8.0. The significance level was set at p\<0.05.

Results {#s3}
=======

Demographic Characteristics of the Patients {#s3_1}
-------------------------------------------

A total of 76 kidney transplant recipients were included in this study and they all were adults and self-reported Egyptians. According to the date of the transplantation, there were missing data for 17 of the patients regarding tacrolimus dose. The characteristics of 59 recipients according to their CYP3A5 genotype are shown in [**Table 1**](#T1){ref-type="table"}. There were no statistically significant differences between the two groups with respect to sex, family history, age of CKD, age at transplantation, time waiting for transplantation, incidence rejection, or donor type.

###### 

Comparison of the clinical characteristics, tacrolimus daily dose, tacrolimus blood levels, and C/D ratio of the study population between *CYP3A5* expressors and non-expressors.

  Characteristics                                          Non-expressors (\*3/\*3) n = 41   Expressors (\*1/\*3, \*1/\*1) n = 18   P value
  -------------------------------------------------------- --------------------------------- -------------------------------------- --------------
  Gender, n (%)                                                                                                                     
   Male                                                    35 (85.37%)                       13 (72.2%)                             0.2841
   Female                                                  6 (14.63%)                        5 (27.8%)                              
  Onset of CKD, years, mean (range) (SD)                   27.2 (9--55)                      31.2 (14--65)                          0.2403
  Onset at transplantation, years, mean (range) (SD)       29.2 (10--55)                     32.8 (14--67)                          0.2983
  Time waiting for transplant, years, mean (range) (SD)    2 (0--6)                          1.56 (0--4)                            0.1965
  Graft rejection, n (%)                                                                                                            
   Yes                                                     8 (19.5%)                         6 (33.3%)                              0.3224
   No                                                      33 (80.5%)                        12 (66.7%)                             
  Family history, n (%)                                                                                                             
   Yes                                                     3 (7.3%)                          2 (11.1%)                              0.6359
   No                                                      38 (92.7%)                        16 (88.9%)                             
  Donor type, n (%)                                                                                                                 
   Living Related                                          33 (80.5%)                        14 (77.8%)                             1.0000
   Living unrelated                                        8 (19.5%)                         4 (22.2%)                              
  Initial Tac D, mg/day, mean (range) (SD)                 6.76 (2--11)                      9.86 (6--14)                           **\<0.0001**
  1-year Tac D, mg/day, mean (range) (SD)                  4.21 (1.5--10.5)                  7.81 (2.5--13)                         **\<0.0001**
  Initial Tac C, ng/ml, mean (range) (SD)                  7.09 (2--22.6)                    5.89 (2--13.5)                         0.3035
  1-year Tac C, ng/mL, mean (range) (SD)                   7.39 (3.3--11.7)                  7.15 (4.9--9.9)                        0.6373
  Initial C/D ratio, ng/ml per mg/day, mean (range) (SD)   1.50 (0.2--9.4)                   0.64 (0.18--1.5)                       0.0586
  1-year C/D ratio, ng/ml per mg/day, mean (range) (SD)    2.10 (0.6--5.8)                   1.10 (0.63--2.84)                      **0.0003**

D, tacrolimus daily dose; C, tacrolimus blood concentration; SD, standard deviation.

Bolded data are those which are statistically significant.

Frequency of the *CYP3A5\*3* Variant in Kidney Transplant Recipients {#s3_2}
--------------------------------------------------------------------

Of the 76 kidney transplant recipients, the *CYP3A5\*3/\*3* genotype was observed in 55 (72.37%) cases, *CYP3A5\*1/\*3* in 20 (26.32%) cases, and *CYP3A5\*1/\*1* in 1 (1.32%) case. Total allelic frequency was 85.53% for *CYP3A5\*3* and 14.47% for *CYP3A5\*1* ([**Figure 1**](#f1){ref-type="fig"}). No deviation from Hardy-Weinberg equilibrium was observed for the genotype frequencies (χ^2^ = 0.58323 \< 3.841).

![Genotype and allelic frequencies of 76 renal transplant recipients for *CYP3A5* gene.](fphar-11-01218-g001){#f1}

Association of the *CYP3A5* Genotype With Tacrolimus Dose, Tacrolimus Blood Levels, and C/D Ratio {#s3_3}
-------------------------------------------------------------------------------------------------

For the 59 patients, tacrolimus initial doses (mean ± standard deviation) for *CYP3A5\*1* carriers and *CYP3A5\*3/\*3* groups were 9.861 ± 2.182 (range: 6.0--14.0) and 6.756 ± 2.478 mg/day (range: 2.0--11.0), while doses one year after transplantation were 7.806 ± 3.158 (range: 2.5--13.0) and 4.207 ± 2.083 mg/day (range: 1.5--10.5), respectively. This shows a significant reduction of the dosage for both genotypic groups, 20.84% for expressors (*CYP3A5*\*1/\*3 or \*1/\*1) (P = 0.0017) and 37.73% for non-expressors (*CYP3A5\*3/\*3*) (P \< 0.0001). Differences between initial and first-year doses are shown in [**Figure 2**](#f2){ref-type="fig"}.

![Differences between initial and first-year doses as stratified by *CYP3A5* genotype.](fphar-11-01218-g002){#f2}

Comparing the starting daily dose between *CYP3A5\*3/\*3* and *CYP3A5\*1* carriers, mean dose for *CYP3A5\*1* carriers was significantly higher (45.96%) than for *CYP3A5\*3/\*3* (P \< 0.0001). One-year mean tacrolimus dose for *CYP3A5\*1* carriers was 85.55% higher than for *CYP3A5\*3/\*3* (P \< 0.0001) ([**Figure 3**](#f3){ref-type="fig"}).

![Tacrolimus dose for *CYP3A5* genotypes. Each genotype appears as paired blots (first blot for initial dose-second blot for first-year dose). \*p \< 0.05.](fphar-11-01218-g003){#f3}

Average tacrolimus blood concentrations in *CYP3A5* non-expressors was higher in both time points compared with *CYP3A5* expressors. However, there was no significant differences between the two groups neither at the early post-transplant period (p = 0.3035) nor at the maintenance period (p = 0.6373).

*CYP3A5\*1* recipients exhibited significantly lower C/D ratios (47.89% lower) than those homozygous for the variant allele (\*3/\*3) at one year of treatment (1.097 ± 0.5829 and 2.105 ± 1.030 ng/ml per mg/day, respectively, p = 0.0003). However, there was no significant difference between the two groups at the early post-transplant period (p = 0.0586). Significant increase was observed at C/D ratios comparing the two time points among *CYP3A5\*1* carriers (p = 0.0003) and among *CYP3A5\*3/\*3* recipients (p = 0.0123) **(** [**Figure 4**](#f4){ref-type="fig"}).

![Dose-Adjusted Tacrolimus Trough-Concentrations for *CYP3A5* genotypes. Each genotype appears as paired blots (first blot for initial dose-second blot for first-year dose). \*p \< 0.05.](fphar-11-01218-g004){#f4}

Discussion {#s4}
==========

The biggest challenge for clinicians is the long-term maintenance of renal grafts after a kidney transplantation. Tacrolimus is one of the currently used immunosuppressive therapies, but its administration may be the causative factor of many side effects and graft rejection ([@B18]). In addition to the highly variable oral bioavailability, pharmacokinetics of tacrolimus is characterized by diversity among individuals in the first-pass metabolism and systemic clearance. These differences are largely due to *CYP3A5* polymorphisms and their effect on the metabolism of tacrolimus.

Pharmacogenomics studies have reported significant association between the *CYP3A5* genotype and the daily doses required for kidney transplant recipients. Most of them noticed that tacrolimus doses were significantly higher in patients carrying \*1 allele (*CYP3A5\*1/\*1* + *CYP3A5\*1/\*3*) compared to recipients homozygous for \*3 allele (*CYP3A5\*3/\*3*) ([@B17]). Our study aimed to analyze the distribution of *CYP3A5* allele frequency in the Egyptian population. In the study population (n = 76) the three genotypic groups, *CYP3A5\*1/\*1*, *CYP3A5\*1/\*3*, and *CYP3A5\*3/\*3* were observed in 1.32, 26.32, and 72.37% respectively. The distribution of *CYP3A5* gene showed that the *CYP3A5\*3* allele was 85.53%. In previous studies in the Egyptian population, different frequencies were reported for the *CYP3A5\*3* allele, ranging from as low as 11% to as high as 78% ([@B23]; [@B1]; [@B5]). Studies published in other North African populations (Algerians, Morocco, Tunisians, Libyans) showed that the *CYP3A5\*3* allele was the most prevalent with a frequency that reaches even 90% ([@B14]; [@B8]), whereas in the African population as a whole is observed great diversity from 4 to 95% ([@B24]).

Several studies have been conducted in North Africans in order to evaluate the effect of *CYP3A5* variants on tacrolimus dosage and on tacrolimus blood concentrations normalized by the dose and proved that there is significant difference between renal transplant patients with the *CYP3A5\*1* allele compared to homozygotes for the *CYP3A5\*3* allele, especially during the early post-transplant phase ([@B6]; [@B2]). To our knowledge, this is the first study to examine the association of the *CYP3A5\*3* allele with tacrolimus dose requirements and C/D ratios in Egyptian kidney transplant recipients. To date, in the Egyptian population, some studies have been conducted examining the correlation of the *CYP3A5* genotype but in liver transplant patients ([@B7]; [@B11]). Our results showed that tacrolimus doses were reduced between the first administration and one year after transplantation, regardless of genotype. Additionally, individuals homozygous for the *CYP3A5\*3* allele need significantly lower tacrolimus daily dose than those carrying \*1 allele (p \< 0.05). Concentration/dose ratio was significantly lower in *CYP3A5\*1* expressors. All these indicate that *CYP3A5* expressors require a larger tacrolimus dose in order to maintain the same blood concentration.

Although there are minor limitations in our study, single center and small cohort, our results showed that frequency of the *CYP3A5\*3* variant seems to be higher as compared with previous studies in the Egyptian population and in agreement to that reported prevalence of this allele for other North African or Caucasian populations. Furthermore, comparison of tacrolimus dose requirement for renal transplant patients showed statistically significant difference among genotypes. It is important to draw up different treatment plan for different recipients. As *CYP3A5* shows great heterogeneity in African population, there is a need for pharmacogenomic testing prior to tacrolimus administration after kidney transplantation to achieve genotype-guided dose and contribute to a better-individualized immunosuppressive therapy.
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